A detailed history of Mirae Asset Global Etfs Holdings Ltd. transactions in Moon Lake Immunotherapeutics stock. As of the latest transaction made, Mirae Asset Global Etfs Holdings Ltd. holds 15,456 shares of MLTX stock, worth $587,791. This represents 0.0% of its overall portfolio holdings.

Number of Shares
15,456
Previous 13,590 13.73%
Holding current value
$587,791
Previous $685,000 19.85%
% of portfolio
0.0%
Previous 0.0%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 14, 2025

BUY
$45.84 - $57.91 $85,537 - $108,060
1,866 Added 13.73%
15,456 $821,000
Q3 2024

Nov 14, 2024

SELL
$40.15 - $55.4 $126,071 - $173,956
-3,140 Reduced 18.77%
13,590 $685,000
Q2 2024

Aug 14, 2024

BUY
$38.43 - $48.6 $642,933 - $813,078
16,730 New
16,730 $735,000

Others Institutions Holding MLTX

About MoonLake Immunotherapeutics


  • Ticker MLTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 36,925,600
  • Market Cap $1.4B
  • Description
  • MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or rad...
More about MLTX
Track This Portfolio

Track Mirae Asset Global Etfs Holdings Ltd. Portfolio

Follow Mirae Asset Global Etfs Holdings Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Mirae Asset Global Etfs Holdings Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Mirae Asset Global Etfs Holdings Ltd. with notifications on news.